Mersana Therapeutics (Nasdaq: MRSN) is a clinical-stage biopharmaceutical company using its differentiated and proprietary antibody-drug conjugate platforms to rapidly develop novel antibody-drug conjugates with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second antibody-drug conjugate product candidate targeting NaPi2b-expressing tumors is in the dose escalation portion of a Phase 1 proof-of-concept clinical study.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.